BioAdvance provides funding to startup life sciences companies in Southeastern Pennsylvania through its
$20 million Greenhouse Fund. We invest in therapeutics, devices, diagnostics and platform technologies focused on human health.

Since our inception in 2002, BioAdvance has become one of the nation's leading investors providing pre-seed and seed-stage funding. To date we have committed over $14 million to 24 seed-stage companies and 14 pre-seed companies and academic projects.  BioAdvance portfolio companies have gone on to attract more than $900 million in subsequent capital to the region, and six of our 24 seed-stage companies have had successful exits through acquisition. BioAdvance was established with $33 million from the Commonwealth of Pennsylvania's share of tobacco settlement monies.